| Participant | Years since diagnosis | PTA | PD-related drugs | Previous behavioral therapy |
|---|---|---|---|---|
| F01 | 10 | 23 | Sinemet, Mirapex, Zelapar | None |
| F02 | 13 | 33 | None | None |
| F03 a | 5 | 35 | Requip, Stalevo, | None; DBS |
| F04 | 4 | 37 | Carbidopa-Levodopa | None |
| F05 | 7 | 8 | Mirapex, Stalevo | None |
| F06 | 29 | 35 | Mirapex, Sinemet | Speech therapy |
| F07 | 0 | 17 | Carbidopa-Levodopa | Speech therapy |
| F08 | 1 | 27 | Carbidopa-Levodopa | Speech therapy |
| M01 | 3 | 22 | Azilect Tablet, Carbidopa-Levodopa, Mirapex | LSVT |
| M02 | 6 | 23 | None | LSVT |
| M03 | 21 | 8 | Sinemet | LSVT |
| M04 | 11 | 17 | Sinemet, Mirapex, ER | None |
| M05 | 5 | 25 | Carbidopa-Levodopa, Mirapex | None |
| M06 | 6 | 12 | Amantadine, Azilect | Speech therapy |
| M07 | 5 | 33 | Azilect, Carbidopa-Levodopa | None |
| M08 | 1 | 10 | Azilect, Carbidopa-Levodopa | None |
| M09 | 3 | 48 | Carbidopa-Levodopa | Swallowing |
| M10 | 5 | 12 | Amantadine, Mirapex | LSVT |
| M11 | 1 | 8 | Mirapex | None |
| M12 | 6 | 53 | Amantadine, Mirapex | None |
| M13 a | 13 | 18 | Amantadine, Comtan, Sinemet, Sinemet CR | None |
| M14 | 12 | 28 | Sinemet, Tasmar | Speech therapy, LSVT |
| M15 | 2 | 28 | Carbidopa-Levodopa, Lodosyn | None |
| M16 | 1 | 17 | Amantadine, Ropinerole | None |
| M17 | 6 | 12 | Sinemet | Speech therapy |
| M18 | 5 | 28 | Sinemet | Speech therapy, LSVT |
| M19 | 11 | 12 | Amantadine, Carbidopa-Levodopa | Speech therapy, LSVT |
| M20 | 14 | 27 | Requip XL, Sinemet, Stalevo | None |
| M21 a | 6 | 37 | Mirapex, Selegiline | Speech therapy, LSVT |
| M22 | 14 | 12 | Mirapex, Selegiline | Speech therapy, LSVT |
| M23 | 3 | 32 | Requip XL | None |
| M24 | 6 | 22 | Artane, Azilect, Requip XL, Symmetrel | None |
| M25 | 2 | 20 | Requip XL | None |
| M26 | 6 | 23 | Artane, Mirapex | None |
| M27 | 12 | 20 | Mirapex, Stalevo | Speech therapy, LSVT |
| M28 | 18 | 8 | Requip XL, Stalevo | None |
| M29 | 3 | 8 | Requip XL, Stalevo | None |
| M30 | 3 | 25 | Selegiline | None |
| M31 | 7 | 28 | Sinemet | None |
| M32 a | 7 | 10 | Stalevo | Speech therapy |
| M33 | 3 | 15 | Requip, Sinemet | Speech therapy, LSVT |
| M34 | 5 | 12 | Requip, Sinemet | None |
Note. Participant demographic information for the individuals with PD: sex (F = female; M = male), years since diagnosis at the time of the study, pure-tone average (PTA was 500, 1000, and 2000 Hz) in the ear in which the SpeechVive was placed, medications related to PD, and previous behavioral therapy for speech/voice. LSVT = Lee Silverman Voice Treatment.
a
Indicates placement of deep-brain stimulation (DBS) device.